Stock Activity: JPMorgan Chase (NYSE:JPM), Bristol-Myers Squibb Company (NYSE:BMY), Piedmont Natural Gas Co. Inc. (NYSE:PNY), Energy Focus (NASDAQ:EFOI), Medtronic plc (NYSE:MDT)

JPMorgan Chase & Co. (NYSE:JPM) is cutting prices for a group of its credit card customers and getting Visa Inc to shoulder at least some of the burden of the lost revenue, underscoring how the largest U.S. bank’s size can help it hang onto business in fiercely competitive markets. At stake are the billions of dollars that banks receive annually from consumer use of a credit card to pay a retailer. Chase, which generated roughly $3.6 billion of revenue last year from those fees, is increasingly occupied with fending off banking rivals like Citigroup Inc, as well as Silicon Valley companies such as Paypal Inc and Square Inc.
JPMorgan Chase & Co. is a financial holding company. The Company is engaged in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. JPMorgan Chase’s activities are organized into four business segments.
On 04 September, JPMorgan Chase & Co. (NYSE:JPM) shares decreased -1.88% and was closed at $61.50. JPM EPS growth in last 5 year was 18.80%. JPMorgan Chase & Co. (NYSE:JPM) year to date (YTD) performance is 0.21%.

Bristol-Myers Squibb has a broad, global development program to study Opdivo in multiple tumor types consisting of more than 50 trials – as monotherapy or in combination with other therapies – in which more than 8,000 patients have been enrolled worldwide.
Bristol-Myers Squibb Company (NYSE:BMY) shares decreased -2.47% in last trading session and ended the day at $57.30. BMY Gross Margin is 77.40% and its has a return on assets of 5.40%. Bristol-Myers Squibb Company (NYSE:BMY) quarterly performance is -11.79%.

Bristol-Myers Squibb Company (NYSE:BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Opdivo for the treatment of previously treated patients with non-squamous (NSQ) non-small cell lung cancer (NSCLC). This sBLA seeks to expand the current indication for Opdivo in patients with previously treated squamous (SQ) NSCLC. The projected FDA action date is January 2, 2016.

Piedmont Natural Gas Co. Inc. (NYSE:PNY) caters to the Utilities space. It has a net profit margin of 10.30% and weekly performance is -5.98%. On the last day of trading company shares ended up $36.35. Piedmont Natural Gas Co. Inc. (NYSE:PNY) distance from 50-day simple moving average (SMA50) is -3.24%.

Piedmont Natural Gas Co. Inc. (NYSE:PNY) reported a third-quarter loss of $8.3 million, or $0.10 per share, compared to a loss of $7.3 million, or $0.09 per share for the same period in 2014. On average, seven analysts polled by Thomson Reuters expected the company to report a loss per share of $0.07 for the quarter. Analysts’ estimates typically exclude special items.
Piedmont Natural Gas Company, Inc. is an energy services company whose principal business is the distribution of natural gas to over one million residential, commercial, industrial and power generation customers in portions of North Carolina, South Carolina and Tennessee, including customers served by municipalities who are the Company’s wholesale customers.

Energy Focus, Inc. (NASDAQ:EFOI) shares advanced 7.87% in last trading session and ended the day at $25.77. EFOI Gross Margin is 39.90% and its has a return on assets of 10.30%. Energy Focus, Inc. (NASDAQ:EFOI) quarterly performance is 261.94%.

Energy Focus, Inc. is a leading provider of energy efficient LED lighting products and a developer of energy efficient lighting technology. Our LED Lighting products provide energy savings, aesthetics, safety and maintenance cost benefits over conventional lighting. Our long-standing relationship with the U.S. Government continues to enable us to provide energy efficient LED lighting products to the U.S. Navy and the Military Sealift Command fleets.

On Sept. 1 Energy Focus, Inc. (NASDAQ:EFOI) announced the addition of Lt. General Charles Davis (USAF Ret) to its Advisory Board. General Davis’ knowledge and network within the U.S. Air Force will further support Energy Focus’ strategies and plans to retrofit fluorescent and HID (high-intensity discharge) lighting fixtures with its industry leading tubular LED (“TLED”) products in U.S. military bases worldwide, including more than 300 million square feet of building space for U.S. Air Force alone.

Medtronic plc (NYSE:MDT) caters to the Healthcare space. It has a net profit margin of 11.30% and weekly performance is -6.23%. On the last day of trading company shares ended up $68.98. Medtronic plc (NYSE:MDT) distance from 50-day simple moving average (SMA50) is -8.52%.

Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Medtronic PLC (NYSE:MDT)‘s stock had its “buy” rating restated by BTIG Research in a report released on Monday, Marketbeat.com reports.